YOU ARE NOW LEAVING TYVASO

FOR US HEALTHCARE
PROFESSIONALS ONLY

For the treatment of pulmonary arterial hypertension
(PAH) (WHO Group 1) to improve exercise ability.
For the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.
For US Healthcare Professionals Only

Privacy Policy

This Privacy Policy describes what information we may collect about you; how we use your information; how we protect it; and what choices you have. Health is a very personal, private subject, and we want you to feel as comfortable as possible visiting our various Web sites and using their respective services. This Privacy Policy applies only to websites that directly link to this policy when you click on "privacy policy" in the website footer.

Personally Identifiable Information

United Therapeutics Corporation ("UT") may collect personally identifiable information such as name, address, telephone number, e-mail address, or other information only when voluntarily submitted by the visitor (i.e. on a web form you fill out and submit). UT uses or discloses personally identified information only with the visitor's consent. UT will comply with any limitations on use communicated when personally identifiable information is collected.

UT will not sell, trade, or rent your personally identifiable information to others. UT may however, share your personally identifiable information with other UT businesses or affiliates, our agents, contractors or business partners in order that they may perform services for us.

UT may use your personally identifiable information for the purposes of sending you information about this website, marketing communications about its products, information about disease states treated with UT's products, information about support groups for patients and peer givers, educational opportunities, conferences, and seminars, an similar information.

Non-Personally Identifiable Information

UT collects non-personally identifiable information in aggregate form to track data such as the total number of visits to our web sites, the number of visitors to each page of our web sites, and the domain names of our visitors' Internet service providers. We use this information, which remains in aggregate form, to understand how our visitors use our web sites so that we may make them better. We may also share this information with our partners or other outside companies. This information is gathered primarily through the use of "cookies." You may be able to change the manner in which your browser manages cookies through your browser's privacy settings. NO PERSONALLY IDENTIFIABLE INFORMATION IS OBTAINED IN THIS PROCESS.

UT uses third party advertising companies to advertise on our behalf across the Internet. These third parties may collect anonymous information about your visits to our website, and your interaction with our ads. This is primarily accomplished through technologies including cookies and Action Tags (commonly referred to as a Web Beacons or GIF tags), which are placed on various places within our website. NO PERSONALLY IDENTIFIABLE INFORMATION IS DISCLOSED IN THIS PROCESS.

Security

UT uses technical and organizational security precautions to protect your data from manipulation, loss, destruction or access by unauthorized persons. Any personal data that is provided to UT by you will be secured in transit to prevent its possible misuse by third parties. Our security procedures are revised from time to time based on new technological developments.

Voluntary Disclosures

Any communications or material that you transmit to, or post on, the site by electronic mail or otherwise, including any data, questions, comments, suggestions, or the like, is, and will be treated as, non-confidential and non-proprietary information, and UT shall have no obligation of any kind with respect to such information except as otherwise stated in this Privacy Policy.

Links to Other Web Sites

UT web sites may provide links to other web sites as a service to our viewers. These linked web sites are intended to provide helpful information. However, UT does not endorse and is not responsible for the content of third-party sites. Nor does UT have any control over the information you may choose to provide these sites. This Privacy Policy does not apply to linked sites.

Changes to Privacy Policy

Any changes to this Privacy Policy will be communicated promptly on this page. Please check back periodically.

IMPORTANT SAFETY INFORMATION FOR TYVASO

WARNINGS AND PRECAUTIONS
DRUG INTERACTIONS / SPECIFIC POPULATIONS
ADVERSE REACTIONS

INDICATION

Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.

While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

TYVISIhcpJUN16

Please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use manual.

For additional information about Tyvaso, visit www.tyvaso.com or call 1-877- UNITHER (1-877-864-8437).

IMPORTANT SAFETY INFORMATION FOR TYVASO

WARNINGS AND PRECAUTIONS
  • The efficacy of Tyvaso has not been established in patients with significant underlying lung disease (such as asthma or chronic obstructive pulmonary disease). Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect.
  • Tyvaso is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, Tyvaso may cause symptomatic hypotension.
  • Titrate slowly in patients with hepatic or renal insufficiency, as exposure to treprostinil may be increased in these patients.
  • Tyvaso inhibits platelet aggregation and increases the risk of bleeding, particularly in patients receiving anticoagulants.
  • Co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil may increase exposure to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events, whereas decreased exposure is likely to reduce clinical effectiveness.
DRUG INTERACTIONS / SPECIFIC POPULATIONS
  • The concomitant use of Tyvaso with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
  • Co-administration of the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to oral treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to oral treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8.
  • There are no adequate and well-controlled studies with Tyvaso in pregnant women. It is not known whether treprostinil is excreted in human milk.
ADVERSE REACTIONS
  • The most common adverse events seen with Tyvaso in ≥4% of PAH patients and more than 3% greater than placebo in the placebo-controlled clinical study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/ pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%).

INDICATION

Tyvaso is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities.

While there are long-term data on use of treprostinil by other routes of administration, nearly all controlled clinical experience with inhaled treprostinil has been on a background of bosentan (an endothelin receptor antagonist) or sildenafil (a phosphodiesterase type 5 inhibitor). The controlled clinical experience was limited to 12 weeks in duration.

TYVISIhcpJUN16

Please see the Full Prescribing Information, Patient Package Insert, and the Tyvaso Inhalation System Instructions for Use manual.

For additional information about Tyvaso, visit www.tyvaso.com or call 1-877- UNITHER (1-877-864-8437).